Interleukin evaluation

This drug also is reported to activate macrophages, to iaduce polyclonal B-ceU activation as well as enhance specific antibody production m vivo, and to iaduce the synthesis of iaterferon and interleukin 1 (52). The iaduction of these important cytokiaes (and others) largely accounts for the profile of biological activity displayed by the pyrimidinones. Bropirimine is currentiy ia clinical evaluation for cancer, arthritis, and immunorestoration ia AIDS patients. 

F19. Friedland, J. S Suputtamongkol, Y., Remick, D., Chaowagul, W., Strieer, R. M., Kunkel, S. L., White, N. J., and Griffing, G. E., Prolonged evaluation of interleukin-8 and interleukin-6 concentrations in plasma and of leukocyte interleukin-8 mRNA levels during septicemic and localized Pseudomonas pseudomallei infection. Infect. Immun. 60,2402-2408 (1992). 

Kratje, R. B., and Wagner, R., Evaluation of Production of Recombinant Human Interleukin-2 in Fluidized Bed Bioreactor, Biotechnol. Bioeng., 39 233... 

Stimulation for 24 hours with LPS leads to the release of interleukin-1 [3, IL-6, IL-8, TNF-a and by prolonging the incubation period from 48 to 72 hours, the whole blood model can detect the release of other lymphokines [45], including IL-2, IL-4, IL-13 and IFN-y. Skewing of the T-helper cell response to antigens can likewise be detected by evaluating the pattern of cytokine release, corresponding to a predominance of Th 1 or Th2 cytokine production. The predictive value of these approaches is currently under investigation. 

Erickson, K.L. et al., Development of an interleukin-2 receptor expression assay and its use in evaluation of cellular immune responses in bottlenose dolphin (Tursiops truncatus), J. Wildlife. Dis., 31, 142, 1995. 

Promoters from cytomegalovirus (CMV) or simian virus 40 (SV40) have been widely used because they are known to be strong promoters (Qin et al., 1997). When we evaluated mouse interleukin-4 (IL-4) and interleukin-10 (IL-10) expres-sion plasmids, pCMV-mIL-4 and pCMV-mIL-10, respectively, we found a high expression level of IL-4 or IL-10 in vitro and in vivo Koh et al. (2001). However, CMV promoter appears to show a decrease in activity when administered in vivo. The duration of gene expression by CMV promoter is short compared with cellular promoters such as j3-actin promoter. Also, CMV promoter shows lower activity than chicken P-actin promoter in the liver (Xu et al., 2001). 

S. Alex, et al., Compatibility and activity of aldesleukin (recombinant interleukin-2) in presence of selected drugs during simulated Y-site administration Evaluation of three methods. Am. J. Health Sys. Pharmacol. 52 2423-2426, 1995. 

An example of the type of research that is currently being carried out deals with the in vitro evaluation of ribozymes on gene expression. Hammerhead ribozymes have been shown to have the ability to attack the coding region of mRNA of interleukin 6 (IL-6). In this manner, theoretically, downregulation of IL-6 may be a potential treatment of those diseases in which IL-6 overexpression is involved. 

Rakhit A, Yeon MM, Ferrante J, Fettner S, Nadeau R, Motzer R et al. Down-regulation of the pharmacokinetic-pharmacodynamic response to interleukin-12 during long-term administration to patients with renal cell carcinoma and evaluation of the mechanism of this adaptive response in mice. Clin Pharmacol Ther 1999 65 615-29. 

Atkins MB, Robertson MJ, Gordon M, Lotze MT, DeCoste M, DuBois JS et al. Phase 1 evaluation of intravenous recombinant human interleukin 12 (rhIL-12) in patients with advanced malignancies. Clin Cancer Res 1997 3 409-17. 

Other examinations focused on the biochemical differentiation of ascites, such as determining cholinesterase (62) and interleukin-6 (18) as sensitive parameters for bacterial infection as well as evaluating the receptors (p55 and p75) for the tumour necrosis factor. (19) An ascites/serum quotient for ai-foetoprotein of > 1 suggests hepatocellular carcinoma an amylase quotient of > 1 is found in pancreatitis. 

---